Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

April 19, 2022 by Alan Khadavi

Fasenra for Nasal Polyps, a new treatment option

Fasenra for nasal polyps is currently being studied as a future therapeutic option. Chronic sinusitis with nasal polyps is an inflammatory condition associated with symptoms that may be severe, including rhinorrhea, nasal blockage and congestion, loss of smell, facial pressure/pain. Nasal sprays have shown limited help and surgery only helps temporarily as many of them grow back.

Nasal polyps have a complex etiology, but studies have shown that type 2 allergic inflammation has a strong connection to it. Fasenra (benralizumab) is a humanized monoclonal antibody produced in Chinese hamster ovary cells. The antibody is directed against the alpha subunit of the IL-5 receptor which is primarily expressed on human eosinophils and basophils.

Fasenra (Benralizumab) for Severe Asthma

Fasenra for nasal polyps is currently being investigated, in the Journal of Allergy and Clinical Immunology a study published “Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial”.

There are several other biological medications approved for nasal polyps:

  • Dupilumab for Nasal Polyps
  • Mepolizumab (Nucala) for Nasal Polyps
  • Xolair for Nasal Polyps

Nucala also inhibits eosinophils in a slightly different way compared to Fasenra, so likely Fasenra will have the same indication soon.

The study overall showed that Fasenra significantly improved nasal polyps and nasal blockage compared to placebo at week 40. Fasenra improved Sinonasal Outcome Test 22 scores as well.

So when Fasenra (benralizumab), when added to standard of care therapy reduced Nasal Polyps, decreased nasal blockage, and reduced difficulty with sense of smell compared to place in patients.

With all of these options to treat nasal polyps in particular biologic agents, it can be difficult to ascertain which one will be best for patients. We discussed this in a previous post and will have more blog posts in the future as well.

Xolair, Dupixent or Nucala for Nasal Polyps?

Nasal Polyps Treatment; Past, Present and Future

Xhance for Nasal Polyps

Potential new Nasal Polyps Treatment option

 

Filed Under: biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page